The above results suggest that APOBEC1/3A/3G/3H will be amplified and mutated in PAAD tissues, which will lead to an increase in APOBEC1/3A/3G/3H expression and poor clinicopathological features of PAAD patients, which may be another important factor leading to worse prognosis in PAAD patients. This evidence concerns the gene APOBEC1 and pancreatic adenocarcinoma.